Recent news highlights include FDA alignment on belapectin Phase III development path, positive Phase 2b data publication, and securing credit facilities to support ongoing development.

• Galectin Therapeutics advanced its belapectin program following FDA feedback and secured a $10 million credit line to support development activities [N6].
• The company announced alignment with FDA on the Phase III clinical development path for belapectin in MASH cirrhosis and portal hypertension, leading to a stock price increase of 11% [N4][N5].
• Top-line results from the NAVIGATE Phase 2b/3 trial showed statistically significant reductions in esophageal varices incidence in the per-protocol population and U.S. subgroup, supporting belapectin’s clinical profile [N3].
• HC Wainwright & Co. maintained a buy recommendation on Galectin Therapeutics, reflecting positive analyst sentiment [N7].
• Galectin’s stock showed notable gains in recent biotech sector performance reports, highlighting market interest [N1][N2].

Galectin Therapeutics has demonstrated clinical progress with belapectin in MASH cirrhosis, including statistically significant reductions in esophageal varices incidence in key patient populations and improvements in fibrosis biomarkers. The drug’s favorable safety profile and FDA alignment on Phase III development path support continued clinical advancement. The company’s pipeline expansion into immuno-oncology and small molecule galectin-3 inhibitors could broaden its therapeutic reach. Securing credit facilities provides financial resources to support ongoing development. Positive clinical data and regulatory interactions may enhance the company’s value proposition in a high unmet need area with limited treatment options.

Galectin Therapeutics faces significant liquidity challenges as current liabilities substantially exceed current assets, with a current ratio of 0.1 as of June 30, 2026. The company remains clinical-stage with no approved products and depends on successful clinical trial outcomes and financing to continue operations. The NAVIGATE trial’s primary endpoint did not reach statistical significance in the intent-to-treat population, and the company’s development plans depend on further regulatory and clinical milestones. Competition in fibrosis and oncology therapeutic areas is intense, and failure to secure additional funding or regulatory approvals could materially impact the company’s prospects.

Galectin Therapeutics’ moat is based on its proprietary galectin-3 inhibitor technology platform, including patented complex carbohydrate compounds derived from natural plant materials. The company’s lead candidate, belapectin, targets galectin-3, a protein implicated in fibrosis and cancer pathogenesis, which is supported by preclinical gene knockout studies and clinical biomarker data. The company has established clinical trial data demonstrating safety and efficacy signals in MASH cirrhosis, a disease area with limited treatment options. Its intellectual property portfolio includes composition of matter patents and clinical development know-how. Additionally, the company’s joint venture developing small molecule galectin-3 inhibitors may expand its product pipeline and delivery methods. However, as a clinical-stage company without approved products, its moat depends on successful clinical development, regulatory approvals, and commercialization capabilities.

• Clinical Development Risk: Belapectin and other product candidates are in clinical development and may fail to demonstrate safety or efficacy required for regulatory approval.
• Regulatory Risk: The company’s ability to advance its drug candidates depends on regulatory agency feedback and approvals, which may delay or prevent commercialization.
• Financial Risk: Galectin has liquidity constraints with current liabilities far exceeding current assets, creating risk of insufficient capital to fund operations and clinical trials.
• Market and Competitive Risk: The company operates in competitive therapeutic areas with other companies developing fibrosis and oncology treatments, which may limit market opportunities.

• Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company focused on drug research and development targeting galectin proteins, especially galectin-3, which are involved in fibrosis, immune function, and cancer.
• The company uses proprietary, patented complex carbohydrates derived from natural plant products to inhibit galectin proteins.
• Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor developed primarily for treatment of metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis and portal hypertension, and certain cancers including melanoma and head and neck squamous cell carcinoma.
• Belapectin has demonstrated in preclinical models the ability to reverse liver fibrosis and cirrhosis and in clinical studies to decrease portal hypertension and prevent esophageal varices.
• Galectin has completed multiple clinical trials including Phase 1, Phase 2, and Phase 2b/3 NAVIGATE trial for belapectin in MASH cirrhosis patients.
• The NAVIGATE trial enrolled 357 patients globally and was designed as a seamless adaptive Phase 2b/3 study evaluating belapectin's safety and efficacy for prevention of esophageal varices in MASH cirrhosis.
• Top-line results from the NAVIGATE trial presented in December 2024 showed a 43.2% reduction in varices incidence in intent-to-treat population but did not reach statistical significance; however, the per-protocol population showed a 49.3% reduction with statistical significance (p<0.05).
• In the U.S. subgroup of the NAVIGATE trial, varices incidence was significantly reduced by 68.1% (p=0.02) in patients treated with belapectin compared to placebo.
• Belapectin treatment was associated with improvements in key biomarkers such as liver stiffness measurement (LSM) and Enhanced Liver Fibrosis (ELF) score, indicating potential reduction in fibrosis risk and liver function improvement.
• Belapectin reduced clinically significant portal hypertension (CSPH) and lowered risk of hepatic decompensation in MASH cirrhosis patients, with a favorable safety profile comparable to placebo and no drug-related serious adverse events reported.
• The company is also developing belapectin in immuno-oncology indications, including a Phase 2 trial planned for head and neck squamous cell carcinoma in combination with a checkpoint inhibitor, pending financing.
• Galectin has a majority-owned joint venture, Galectin Sciences LLC, developing small molecule galectin-3 inhibitors with potential alternative drug delivery methods.
• The company has secured multiple lines of credit and recently converted convertible promissory notes into common stock, with a significant ownership stake held by Chairman Richard E. Uihlein.
• As of June 30, 2026, Galectin reported cash and equivalents of $13.27 million, current assets of $14.66 million, and current liabilities of $151.62 million, resulting in a current ratio of 0.1 and cash ratio of 0.09, indicating liquidity constraints.
• Net loss for the six months ended June 30, 2026, was $9.11 million with basic and diluted EPS of -$0.14 per share.
• The company is listed on Nasdaq under ticker GALT.
• Recent news highlights include FDA alignment on belapectin Phase III path in MASH, positive Phase 2b data publication, and securing a $10 million credit line.
• The company has ongoing clinical and regulatory interactions with the FDA, including feedback incorporated into trial designs and development plans.